Health Care

Amicus Therapeutics: FDA clears NDA submission for Fabry disease treatment

Amicus Therapeutics: FDA clears NDA submission for Fabry disease treatment

The stock's market capitalization is 1.85B, it has a 52-week low of 4.41 and a 52-week high of 13.28. (FOLD) have 142.77 million outstanding shares now held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

In Healthcare sector, shares of Amicus Therapeutics, Inc. Thanks to the latest 25.93% increase, it now trades at $12.92.

In other Amicus Therapeutics news, insider Jay Barth sold 30,000 shares of the company's stock in a transaction dated Monday, June 19th. The stock notched a 12-month high of $12.92 while $18.00 target is by far the most aggressive out of analysts who are now evaluating the company, $5.08 higher than the next highest 52-week price estimate. Finally, Robert W. Baird reissued an outperform rating and set a $12.00 price objective (up previously from $10.00) on shares of Amicus Therapeutics in a research note on Wednesday, May 17th. Checking some other stock price data, we can see that the recent distance from the 50 day high was noted at 21.17% and the separation from the 50 day low is presently 103.59%.

Now have a look at past performance (weekly performance to year to date performance) how Amicus Therapeutics, Inc. The firm owned 7,882,988 shares of the biopharmaceutical company's stock after buying an additional 1,472,958 shares during the period.

03/30/2016 - Amicus Therapeutics, Inc. had its "neutral" rating reiterated by analysts at Goldman Sachs.

Whole Foods Had A Chicken / Tuna Mix-Up & Jessica Simpson Was Fkn Ready
Everyone wondered if it was scripted. "You could feel there was tension between the two of them", Kolinsky told Complex . He father was reportedly very involved in her life. "The only thing they really had in common was their music".

EX-99.1 2 a17-17143_1ex99d1.htm EX-99.1 Exhibit 99.1 U.S. FDA Confirms Amicus Therapeutics May Submit New Drug Application for Migalastat for Fabry Disease Data Deemed Sufficient to Support NDA Submission NDA Submission Targeted for 4Q17 Conference Call Today at 8:30am ET CRANBURY, ...

According to the analysts, Amicus Therapeutics (NASDAQ:FOLD) is expected to announce $-0.36/share EPS for the current quarter. (NASDAQ:FOLD) from a hold rating to a buy rating in a research report sent to investors on Friday, June 16th. This recommendation lands on a scale between 1 and 5.

Amicus Therapeutics, Inc. (FOLD)'s RSI (Relative Strength Index) is 82.43. However a year ago for the same quarter the company has reported $-1.17 EPS. The firm had revenue of $4.20 million for the quarter, compared to analysts' expectations of $4.16 million. Privately owned Bruin E&P Partners will pay $1.4 billion in cash to Halcon in exchange for its assets in the Williston Basin area. Tudor Investment Corp Et Al acquired a new position in Amicus Therapeutics during the fourth quarter valued at about $255,000. Amicus Therapeutics has a 1-year low of $4.41 and a 1-year high of $13.28. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & global trademark & copyright law. These shares are worth $300,000 and were traded at $10 each. Amicus Therapeutics, Inc. has far performed well this year, with the share price up 106.44% since January.

This is all very good news for the thousands of people suffering from Fabry disease, which is extremely rare - with just 3,000 people affected in the United States and only 700 patients now being treated in Japan. Total Debt/Equity is 50.47 and the Book value per Share is 2.18. Following the sale, the insider now owns 474,438 shares in the company, valued at approximately $3,795,504. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The disclosure for this sale can be found here. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease.